Lab-Grown Blood Trials: A Solution to Transfusion Shortages

Medical science recently achieved a major milestone. For the first time, scientists successfully transfused lab-grown red blood cells into healthy human volunteers. This clinical trial opens up new possibilities for treating rare blood disorders and addressing severe shortages in blood banks worldwide.

The Breakthrough: Inside the RESTORE Trial

The clinical study making headlines is called the RESTORE trial. This project is a joint effort in the United Kingdom led by NHS Blood and Transplant, the University of Bristol, and the University of Cambridge. The goal of the trial is not to completely replace human blood donations. Instead, researchers want to see if manufactured red blood cells can safely function inside the human body and outlast standard donated blood.

In this Phase 1 clinical trial, healthy volunteers receive a very small amount of lab-grown blood. Researchers transfuse roughly 5 to 10 milliliters of manufactured blood, which is only about one or two teaspoons. By keeping the initial amounts small, scientists can safely monitor the volunteers for adverse reactions while tracking how the new cells behave.

To track the cells accurately, the research team tags the manufactured blood with a mildly radioactive tracer. This is a standard medical procedure that allows doctors to see exactly how long the lab-grown cells survive compared to standard red blood cells.

How Scientists Grow Blood in a Laboratory

Growing human blood is a complex process that relies on natural biology. The process begins with a standard blood donation of about 470 milliliters from a healthy human donor. From there, scientists perform several precise steps:

• Extraction: Researchers use tiny magnetic beads to pull out specific, flexible stem cells from the donated blood. These stem cells have the unique ability to turn into red blood cells.
• Cultivation: The extracted stem cells are placed in a nutrient-rich solution inside a laboratory incubator. This environment mimics the conditions inside the human body.
• Multiplication: Over the course of 18 to 21 days, the cells multiply rapidly. A starting batch of half a million stem cells can grow into 50 billion red blood cells.
• Filtering: Finally, the scientists filter the newly grown cells to isolate the mature red blood cells, ensuring they are ready for human transfusion.

The Lifespan Advantage of Manufactured Cells

One of the biggest advantages of lab-grown blood is its age. Red blood cells naturally live for about 120 days inside the human body. When you receive a standard blood transfusion from a donor, that bag of blood contains cells of varying ages. Some cells might be brand new, while others might be 100 days old and ready to die off.

Because lab-grown blood is manufactured in a controlled environment, every single cell is essentially brand new. They are exactly zero days old at the time of transfusion. Scientists expect these manufactured cells to survive the full 120 days in the patient’s bloodstream.

This extended lifespan means patients would not need to visit the hospital for transfusions as often. Reducing the frequency of transfusions is a massive quality-of-life improvement for people living with chronic conditions.

Who Will Benefit Most from Lab-Grown Blood?

While standard blood donations will continue to help trauma patients and surgery patients, lab-grown blood is specifically targeted at two major groups of people.

First, this technology will help patients with rare blood disorders like sickle cell disease and thalassemia. People with these conditions require regular, lifelong blood transfusions to stay healthy. However, receiving frequent transfusions carries severe risks. Patients often suffer from iron overload, a condition where excess iron builds up in the organs and causes damage. They are also at high risk for alloimmunization, which happens when the immune system starts attacking the donated blood. Because lab-grown blood lasts longer, patients need fewer transfusions, which directly lowers the risk of both complications.

Second, lab-grown blood will be a lifesaver for people with ultra-rare blood types. Some blood types, like the Bombay phenotype, are so rare that finding a matching donor is nearly impossible. With this new technology, scientists could take a single stem cell donation from a person with an ultra-rare blood type and manufacture large quantities of blood specifically for them.

Overcoming Roadblocks: Cost and Production

Despite the successful early trials, lab-grown blood will not be available in local hospitals right away. The primary hurdle is the cost. Growing blood in a laboratory is currently highly expensive and requires specialized, sterile facilities.

Another major challenge is scaling the production. Right now, scientists are only manufacturing small amounts of blood for the RESTORE trial. Expanding this process to create the large volumes needed for standard hospital use requires technological advancements that are still years away. Researchers are actively working on automated systems that could eventually mass-produce red blood cells at a lower cost.

Why Human Donors Will Still Be Needed

It is important to understand that lab-grown blood does not eliminate the need for regular blood drives. The entire manufacturing process still requires a starting donation of human stem cells. Furthermore, blood banks process millions of units of blood every year for emergency surgeries, accidents, and cancer treatments. Traditional blood donation will remain the backbone of emergency medical care for the foreseeable future.

Frequently Asked Questions

What is the RESTORE trial? The RESTORE trial is a UK-based clinical study testing the safety and lifespan of lab-grown red blood cells in healthy human volunteers.

Does lab-grown blood replace human blood donors? No. Human donors are still required because the manufacturing process starts with stem cells extracted from donated human blood. Traditional donations are also still needed for emergency care.

How much lab-grown blood is given during the trial? Volunteers in the clinical trial receive a very small dose of 5 to 10 milliliters (about one to two teaspoons) to ensure safety.

Why is lab-grown blood better for sickle cell patients? Manufactured blood cells are entirely fresh and last longer in the body (up to 120 days). This means patients need fewer transfusions over time, reducing the risk of iron overload and immune system rejection.

How long does it take to grow blood in a lab? Once the stem cells are extracted from a donor, it takes roughly 18 to 21 days for them to multiply and mature into red blood cells in the laboratory.